Here is the latest stock price and chart of TEJNAKSH HEALTHCARE. For more details, see the TEJNAKSH HEALTHCARE company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Our FREE Guide: Small Caps That Will Race Ahead of the Sensex
Live BSE Quotes | May 27, 2022 (Close) | ||
---|---|---|---|
Price (Rs)134.75 | Open (Rs) 140.90 | High (Rs) 140.90 | Low (Rs) 127.25 |
% Change-0.04 | Volume 30,568 | Value (Rs) 4,122,643 | 52-Week H/L 194.00 / 56.00 |
Live NSE Quotes |
---|
Not listed |
Change | |||||
---|---|---|---|---|---|
1 Day -0.04% | 1 Month -17.20% | 3 Months -15.01% | 1 Year 116.64% | 5 Years (CAGR)* -14.79% |
* Compound Annual Growth Rate
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* 2.77 | P/E Ratio (x) 48.71 | Market Cap (Rs m) 1,368.63 | P/BV (x) 7.90 | Dividend Yield (%) 0.00 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
![]() |
||
S&P BSE SENSEX ![]() |
||||||
PERIOD |
TEJNAKSH HEALTHCARE last traded price was down 0.0% to Rs 134.8 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 1.4%. And the benchmark S&P BSE SENSEX was at 54,884.7 (up 1.2%).
Over the last 30 days, the TEJNAKSH HEALTHCARE share price is down 16.3%. And over the last one year, TEJNAKSH HEALTHCARE share price is up 118.0%.
The current market capitalisation of TEJNAKSH HEALTHCARE stands at Rs 1,368.63 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 73.83% stake in TEJNAKSH HEALTHCARE, with no shares having been pledged. To know more, check out the latest shareholding pattern of TEJNAKSH HEALTHCARE.
What else is happening in the markets today? Dig in...
Indian share markets rose today as easing bets about aggressive interest rate hikes by central banks lifted sentiment.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More